Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Δ30 with those of DEN1

Virology Journal

Volumn 4, Issue , 2007, Pages

  Blaney Jr , Joseph E ^a   Sathe, Neeraj S ^a   Hanson, Christopher T ^a   Firestone, Cai Yen ^a   Murphy, Brian R ^a   Whitehead, Stephen S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; DENGUE VACCINE; LIVE VACCINE; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PRECURSOR PROTEIN; VIRUS ENVELOPE PROTEIN;

AEDES AEGYPTI; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CHIMERA; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DENGUE VIRUS 1; DISEASE CARRIER; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOSQUITO; MOUSE; NONHUMAN; PROVOCATION TEST; RECOMBINANT DENGUE VIRUS 4; RHESUS MONKEY; SEROCONVERSION; VERO CELL; VIRUS ATTENUATION; VIRUS GENE; VIRUS MUTANT; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE; XENOGRAFT;

AEDES; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CELL LINE, TUMOR; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DISEASE MODELS, ANIMAL; HUMANS; MACACA MULATTA; MICE; MICE, SCID; NEUTRALIZATION TESTS; RECOMBINATION, GENETIC; SURVIVAL ANALYSIS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL STRUCTURAL PROTEINS; VIREMIA; VIRUS REPLICATION;

AEDES AEGYPTI; DENGUE VIRUS TYPE 1; DENGUE VIRUS TYPE 4; MACACA MULATTA; MIRIDAE; MUS;

EID: 33847777612     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-23     Document Type: Article

References (33)

1. Flaviviridae: the viruses and their replication. BD Lindenbach CM Rice, Fields Virology Philadelphia, PA: Lippincott Williams and Wilkins, Knipe DM, Howley PM, Fourth 2001 1 1043 1125
2. WHO, Dengue haemorrhagic fever: diagnosis, treatment prevention and control Geneva: WHO 2 1997
3. Impact of dengue/dengue hemorrhagic fever on the developing world. DJ Gubler M Meltzer, Adv Virus Res 1999 53 35 70 10582094
4. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. JS Mackenzie DJ Gubler LR Petersen, Nature Medicine 2004 10 S98 109 10.1038/nm1144 15577938
5. Flaviviruses. DS Burke TP Monath, Fields Virology Philadelphia: Lippincott Williams and Wilkins, Knipe DM, Howley PM, Fourth 2001 1 1043 1125
6. Yellow fever. TP Monath, Vaccines Philadelphia: W.B. Saunders Co, Plotkin SA, Orenstein WA, 3 1999 815 879
7. Development of a live attenuated dengue virus vaccine using reverse genetics. JE Blaney Jr AP Durbin BR Murphy SS Whitehead, Viral Immunol 2006 19 10 32 10.1089/vim.2006.19.10 16553547
8. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. JE Blaney Jr JM Matro BR Murphy SS Whitehead, J Virol 2005 79 5516 5528 15827166 10.1128/JVI.79.9.5516-5528.2005
9. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. AP Durbin RA Karron W Sun DW Vaughn MJ Reynolds JR Perreault B Thumar R Men CJ Lai WR Elkins, Am J Trop Med Hyg 2001 65 405 413 11716091
10. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. SS Whitehead B Falgout KA Hanley JE Blaney Jr L Markoff BR Murphy, J Virol 2003 77 1653 1657 12502885 10.1128/JVI.77.2.1653-1657.2003
11. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. JE Blaney Jr CT Hanson CY Firestone KA Hanley BR Murphy SS Whitehead, Am J Trop Med Hyg 2004 71 811 821 15642976
12. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. JE Blaney Jr CT Hanson KA Hanley BR Murphy SS Whitehead, BMC Infect Dis 2004 4 39 15461822 10.1186/1471-2334-4-39
13. rDEN4Δ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. AP Durbin SS Whitehead J McArthur JR Perreault J Blaney E J B Thumar BR Murphy RA Karron, J Infect Dis 2005 191 710 718 10.1086/427780 15688284
14. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. AP Durbin J McArthur JA Marron JE Blaney Jr B Thumar K Wanionek BR Murphy SS Whitehead, Human Vaccines 2006 2 167 173 17012875
15. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. SS Whitehead KA Hanley JE Blaney LE Gilmore WR Elkins BR Murphy, Vaccine 2003 21 4307 4316 10.1016/S0264-410X(03) 00488-2 14505913
16. rDEN2/4Delta30(ME), A Live Attenuated Chimeric Dengue Serotype 2 Vaccine Is Safe and Highly Immunogenic in Healthy Dengue-Naive Adults. AP Durbin JH McArthur JA Marron JE Blaney B Thumar K Wanionek BR Murphy SS Whitehead, Human Vaccines 2006 2 255 260 17106267
17. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. JE Blaney GG Manipon CY Firestone DH Johnson CT Hanson BR Murphy SS Whitehead, Vaccine 2003 21 4317 4327 10.1016/S0264-410X(03)00487-0 14505914
18. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. KA Hanley LR Manlucu GG Manipon CT Hanson SS Whitehead BR Murphy JE Blaney Jr, Vaccine 2004 22 3440 3448 10.1016/j.vaccine.2004.02.031 15308370
19. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. M Bray CJ Lai, Proc Natl Acad Sci USA 1991 88 10342 10346 1682924 10.1073/pnas.88.22.10342
20. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. AG Pletnev R Men, Proc Natl Acad Sci USA 1998 95 1746 1751 9465088 10.1073/pnas.95.4.1746
21. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. F Guirakhoo R Weltzin TJ Chambers ZX Zhang K Soike M Ratterree J Arroyo K Georgakopoulos J Catalan TP Monath, J Virol 2000 74 5477 5485 10823852 10.1128/JVI.74.12.5477-5485.2000
22. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. AG Pletnev DE Swayne J Speicher AA Rumyantsev BR Murphy, Vaccine 2006 24 6392 6404 10.1016/j.vaccine.2006.06.008 16831498
23. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. CY Huang S Butrapet KR Tsuchiya N Bhamarapravati DJ Gubler RM Kinney, J Virol 2003 77 11436 11447 14557629 10.1128/JVI.77.21.11436-11447. 2003
24. Chimeric Japanese encephalitis virus/dengue 2 virus infectious clone: biological properties, immunogenicity and protection against dengue encephalitis in mice. TJ Chambers X Jiang DA Droll Y Liang WS Wold J Nickells, J Gen Virol 2006 87 3131 3140 10.1099/vir.0.81909-0 17030845
25. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. AG Pletnev M Bray J Huggins CJ Lai, Proc Natl Acad Sci USA 1992 89 10532 10536 1438242 10.1073/pnas.89.21.10532
26. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. F Guirakhoo S Kitchener D Morrison R Forrat K McCarthy R Nichols S Yoksan X Duan TH Ermak N Kanesa-Thasan, Human Vaccines 2006 2 60 67 17012873
27. A live, attenuated recombinant West Nile virus vaccine. TP Monath J Liu N Kanesa-Thasan GA Myers R Nichols A Deary K McCarthy C Johnson T Ermak S Shin, Proc Natl Acad Sci USA 2006 103 6694 6699 16617103 10.1073/pnas.0601932103
28. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. TP Monath I Levenbook K Soike ZX Zhang M Ratterree K Draper AD Barrett R Nichols R Weltzin J Arroyo F Guirakhoo, J Virol 2000 74 1742 1751 10644345 10.1128/JVI.74.4.1742-1751.2000
29. RNA binding properties of core protein of the flavivirus Kunjin. AA Khromykh EG Westaway, Arch Virol 1996 141 685 699 10.1007/BF01718326 8645104
30. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. N Kanesa-thasan W Sun G Kim-Ahn S Van Albert JR Putnak A King B Raengsakulsrach H Christ-Schmidt K Gilson JM Zahradnik, Vaccine 2001 19 3179 3188 10.1016/S0264-410X(01)00020-2 11312014
31. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. W Sun R Edelman N Kanesa-thasan KH Eckels JR Putnak AD King H-S Houng D Tang JM Scherer CH Hoke BL Innis, Am J Trop Med Hyg 2003 69 24 31 14740952
32. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. JE Blaney Jr DH Johnson GG Manipon CY Firestone CT Hanson BR Murphy SS Whitehead, Virology 2002 300 125 139 10.1006/viro.2002.1528 12202213
33. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. JM Troyer KA Hanley SS Whitehead D Strickman RA Karron AP Durbin BR Murphy, Am J Trop Med Hyg 2001 65 414 419 11716092